Johnson & Johnson presents Phase 4 TREMFYA late breaking data in psoriatic arthritis ($267.14, 0.00)
Transcript Intelligence: Novartis Investor Meeting - AI Panel
Transcript Intelligence: Novartis Investor Meeting - Breakout Session
StreetAccount Summary - Trading higher/lower: EU mid-morning
Powered by FactSet Research Systems Inc.